Optimized Recombinant Human Thrombopoietin(rhTPO) Regimen Versus Eltrombopag for Pre-Treated Patients with Primary Immune Thrombocytopenia: Interim Results from a Prospective, Multicenter, Randomized Trial (TE-ITP study)

被引：0

作者：

Chen, Yunfei ^{[1
]}

Sun, Ting ^{[1
]}

Gao, Da ^{[2
]}

Wang, Wei ^{[3
]}

Zhou, Zeping ^{[4
]}

Gao, Guangxun ^{[5
]}

Wang, Yi ^{[6
]}

Zhou, Hu ^{[7
,8
]}

Song, Yanping ^{[9
]}

Lai, Yinghui ^{[10
]}

Yan, Zhenyu ^{[11
]}

Yan, Jinsong ^{[12
]}

Hai, Jie ^{[13
]}

Zhang, Lei ^{[1
,14
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Tianjin, Peoples R China

[2] Inner Mongolia Med Univ, Affiliated Hosp, Hohhot, Peoples R China

[3] Harbin Med Univ, Affiliated Hosp 2, Dept Hematol, Harbin, Peoples R China

[4] Kunming Med Univ, Affiliated Hosp 2, Dept Hematol, Kunming, Yunnan, Peoples R China

[5] Xijing Hosp, Dept Hematol, Xian, Peoples R China

[6] Shaanxi Prov Peoples Hosp, Xian, Peoples R China

[7] Zhengzhou Univ, Affiliated Canc Hosp, Dept Hematol, Zhengzhou, Peoples R China

[8] Henan Canc Hosp, Zhengzhou, Peoples R China

[9] Xian Cent Hosp, Inst Hematol, Xian, Peoples R China

[10] Second Affiliated Hosp Guangxi Med Univ, Dept Gastroenterol, Nanning, Guangxi, Peoples R China

[11] North China Univ Sci & Technol, Affiliated Hosp, Tangshan, Peoples R China

[12] Second Hosp Dalian Med Univ, Dept Cardiology2, Dalian, Peoples R China

[13] Inst Hematol & Blood Dis Hosp, Tianjin, Peoples R China

[14] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Tianjin, Peoples R China

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-202716

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：3937 / 3938

页数：2

共 9 条

[1] A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia
Wang, Shujie
Yang, Renchi
Zou, Ping
Hou, Ming
Wu, Depei
Shen, Zhixiang
Lu, Xijing
Li, Yan
Chen, Xiequn
Niu, Ting
Sun, Hui
Yu, Li
Wang, Zhao
Zhang, Yin
Chang, Naibai
Zhang, Gaokui
Zhao, Yongqiang
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2012, 96 (02) : 222 - 228
[2] A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia
Shujie Wang
Renchi Yang
Ping Zou
Ming Hou
Depei Wu
Zhixiang Shen
Xijing Lu
Yan Li
Xiequn Chen
Ting Niu
Hui Sun
Li Yu
Zhao Wang
Yin Zhang
Naibai Chang
Gaokui Zhang
Yongqiang Zhao
International Journal of Hematology, 2012, 96 : 222 - 228
[3] Recombinant human thrombopoietin (rhTPO) of different dosing regimens for refractory/relapsed primary immune thrombocytopenia: a multicenter, randomized controlled trial and pharmacokinetics study
Liu, Xiaofan
Bai, Yusheng
Wang, Tao
Song, Yanping
Sun, Feng
Xia, Ruixiang
Zhu, Feiyue
Ma, Jun
Lu, Quanyi
Ye, Xu
Zhan, Xinrong
Li, Linjie
Guo, Xinhong
Cheng, Shuqin
Li, Yan
Guo, Zhiqiang
Chen, Youhua
Qian, Shenxian
Qin, Ling
Zhang, Qing
Cao, Sunqiong
Yang, Renchi
PLATELETS, 2023, 34 (01)
[4] A prospective study of the efficacy and safety of maintenance therapy with recombinant human thrombopoietin in patients with primary immune thrombocytopenia:a multicenter study
蔡华聪
China Medical Abstracts(Internal Medicine), 2017, 34 (03) : 181 - 182
[5] RECOMBINANT HUMAN THROMBOPOIETIN (RHTPO) IN COMBINATION WITH LOW-DOSE RITUXIMAB (LD RTX) IN SEVERE OR REFRACTORY PRIMARY IMMUNE THROMBOCYTOPENIA: A MULTICENTER PROSPECTIVE CLINICAL TRIAL
Hou, M.
Xu, M.
Peng, J.
HAEMATOLOGICA, 2013, 98 : 196 - 196
[6] Switching from Eltrombopag to Hetrombopag in Patients with Primary Immune Thrombocytopenia (ITP): Post-Hoc Analysis of a Multicenter, Randomized Phase III Trial
Yu Hu
Yang, Renchi
Ting Niu
Heng Mei
Liu Xiaofan
Yan Li
Hu Zhou
Ying Feng
Gao, Guangxun
Peng Cheng
Huang, Ruibin
Yang, Linhua
Hu, Jianda
Ming Hou
Yao, Yazhou
Li Liu
Yi Wang
Wu, De-Pei
Shen, Xuliang
Jie Jin
Luo, Jianmin
Zeng Yun
Xin Zhou
Xiang, Ruixiang
Jiang, Zhongxing
Bai, Yuansong
Xiong, Junye
Li, Runzi
Zou, Jianjun
BLOOD, 2022, 140 : 5543 - 5545
[7] Recombinant Human Thrombopoietin (rhTPO) and High-Dose Dexamethasone (HD-DXM) Versus High-Dose Dexamethasone Monotherapy As Frontline Treatment in Newly Diagnosed Adult Immune Thrombocytopenia (ITP): a Prospective, Multicentre, Randomised, Controlled Trial
Wang, Miaomiao
Qin, Ping
Zhou, Hai
Zhou, Fang
Zhao, Hongguo
Wang, Xin
Xu, Ruirong
Li, Daqi
Wang, Lei
Zhou, Yuhong
Feng, Ying
Zhang, Mei
Yang, Lan
Wang, Xiaomin
Zeng, Qingshu
Zhang, Haiyan
Sun, Zhaogang
Wang, Jingxia
Liu, Guoqiang
Guo, Xinhong
Wang, Zhencheng
Yu, Wenzheng
Chu, Xiaoxia
Yuan, Chenglu
Bi, Kehong
Wang, Yili
Ran, Xuehong
Peng, Jun
Hou, Ming
BLOOD, 2017, 130
[8] High-dose dexamethasone plus recombinant human thrombopoietin vs high-dose dexamethasone alone as frontline treatment for newly diagnosed adult primary immune thrombocytopenia: A prospective, multicenter, randomized trial
Yu, Yafei
Wang, Miaomiao
Hou, Yu
Qin, Ping
Zeng, Qingshu
Yu, Wenzheng
Guo, Xinhong
Wang, Jingxia
Wang, Xiaomin
Liu, Guoqiang
Chu, Xiaoxia
Yang, Lan
Feng, Ying
Zhou, Fang
Sun, Zhaogang
Zhang, Mei
Wang, Xin
Wang, Zhencheng
Ran, Xuehong
Zhao, Hongguo
Wang, Lei
Zhang, Haiyan
Bi, Kehong
Li, Daqi
Yuan, Chenglu
Xu, Ruirong
Wang, Yili
Zhou, Yuhong
Peng, Jun
Liu, Xin-guang
Hou, Ming
AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (12) : 1542 - 1552
[9] ELTROMBOPAG AS SECOND LINE THERAPY IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN ATTEMPT TO ACHIEVE LONG-TERM REMISSION. UPDATED RESULTS OF A PHASE II, MULTICENTER, PROSPECTIVE STUDY BY GIMEMA GROUP (THE ESTIT STUDY)
Lucchini, E.
Palandri, F.
Volpetti, S.
Vianelli, N.
Auteri, G.
Rossi, E.
Patriarca, A.
Carli, G.
Barcellini, W.
Rotondo, F.
Consoli, U.
Valeri, F.
Santoro, C.
Crea, E.
Vignetti, M.
Boggio, E.
Dianzani, U.
Giardini, I.
Carpenedo, M.
Rodeghiero, F.
Fanin, R.
Zaja, F.
HAEMATOLOGICA, 2019, 104 : 32 - 32

← 1 →